AstraZeneca Partners With AmoyDx On Companion Diagnostics For Lynparza

Teaming again with the Shanghai biotech, AstraZeneca will seek assays that can be incorporated into companion diagnostics for Lynparza in prostate and breast cancer.

Diagnostic test
AstraZeneca is partnering to develop additional companion diagnostics for Lynparza • Source: Alamy

[Editor's note: A version of this article was originally published in Informa's Scrip.]

Previously partnered on companion diagnostic development for ovarian and breast cancer, AstraZeneca will partner with AmoyDx to develop tools for treatments with Lynparza in the EU, Japan and China.

More from In Vitro Diagnostics

More from Diagnostics